United States US

US

Vertex Announces Third Quarter 2021 Financial Results

Listen to the webcast

Type 1 Diabetes Program Update 

We’ve announced new data for the ongoing Phase 1/2 study of our investigational cell therapy program for the treatment of type 1 diabetes (T1D).

Learn more

Cystic Fibrosis Program Update

We’re moving forward with the Phase 3 development program for our investigational once-daily triple combination regimen for people with cystic fibrosis.

Learn more

New data for investigational gene editing program presented at EHA

Vertex and CRISPR Therapeutics share new clinical data on investigational potential treatments for severe sickle cell disease and transfusion-dependent beta thalassemia at the European Hematology Association (EHA) Annual Meeting

Learn More

COVID-19 Information and Resources

Keeping you informed as the COVID-19 pandemic evolves

Learn More
Biotechnology to Create Transformative Medicines

At Vertex, we're relentless in our pursuit of medical research to create transformative medicines for people with serious and genetic diseases, like cystic fibrosis.

Learn More
Featured contents
Green background
PIPELINE & MEDICINES

Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

Learn More
CF white Icon
WORKING HERE

At Vertex, we have some of the industry’s best and brightest people helping us achieve our mission of discovering transformative medicines to help people with serious diseases like cystic fibrosis.

Learn Here
Briefcase Icon
NEWS

Vertex Announces Expanded Reimbursement Agreement With NHS England

Learn More
We Are Vertex
Meet Our Team
Join Our Team

Follow Us for Updates

@VertexPharma

    Follow Us on Twitter